# Hecla Mining Co: financial statements, quarterly

HL · NYSE · CIK 719413 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hl.md) · [Financials](/companies/hl/financials.md) · [Filings](/companies/hl/filings.md) · [Insiders](/companies/hl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [182](/filings/0000950170-24-123004.md) | [161 d](/filings/0001193125-26-055059.md) | [190](/filings/0000950170-25-062012.md) | [246](/filings/0000950170-25-104199.md) | [245](/filings/0001193125-25-267093.md) | [250 d](/filings/0001193125-26-055059.md) | [205](/filings/0001193125-26-206810.md) | [219](/filings/0001193125-26-333090.md) | [410](/filings/0001193125-25-267093.md) | [448 d](/filings/0001193125-26-055059.md) | [411](/filings/0001193125-26-206810.md) | [334](/filings/0001193125-26-333090.md) |
| Cost of revenue | $m | [148](/filings/0000950170-24-123004.md) | [154 d](/filings/0001193125-26-055059.md) | [170](/filings/0000950170-25-062012.md) | [194](/filings/0000950170-25-104199.md) | [186](/filings/0001193125-25-267093.md) | [181 d](/filings/0001193125-26-055059.md) | [137](/filings/0001193125-26-206810.md) | [185](/filings/0000950170-25-104199.md) | [229](/filings/0001193125-25-267093.md) | [200 d](/filings/0001193125-26-055059.md) | [158](/filings/0001193125-26-206810.md) | not reported |
| Gross profit | $m | [33.5](/filings/0000950170-24-123004.md) | [6.9 d](/filings/0001193125-26-055059.md) | [19.2](/filings/0000950170-25-062012.md) | [51.4](/filings/0000950170-25-104199.md) | [59.3](/filings/0001193125-25-267093.md) | [68.3 d](/filings/0001193125-26-055059.md) | [68.7](/filings/0001193125-26-206810.md) | [85.3](/filings/0001193125-26-333090.md) | [180](/filings/0001193125-25-267093.md) | [248 d](/filings/0001193125-26-055059.md) | [253](/filings/0001193125-26-206810.md) | [180](/filings/0001193125-26-333090.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(12.6)](/filings/0000950170-24-123004.md) | [(42.4) d](/filings/0001193125-26-055059.md) | [5.1](/filings/0000950170-25-062012.md) | [40.6](/filings/0000950170-25-104199.md) | [22.5](/filings/0001193125-25-267093.md) | [38.1 d](/filings/0001193125-26-055059.md) | [47.4](/filings/0001193125-26-206810.md) | [58.0](/filings/0001193125-26-333090.md) | [149](/filings/0001193125-25-267093.md) | [220 d](/filings/0001193125-26-055059.md) | [223](/filings/0001193125-26-206810.md) | [146](/filings/0001193125-26-333090.md) |
| Interest expense | $m | [10.7](/filings/0000950170-24-123004.md) | [(74.5) d](/filings/0001193125-26-055059.md) | [12.6](/filings/0000950170-25-062012.md) | [12.5](/filings/0000950170-25-104199.md) | [10.9](/filings/0001193125-25-267093.md) | [(85.9) d](/filings/0001193125-26-055059.md) | [11.4](/filings/0001193125-26-206810.md) | [10.9](/filings/0001193125-26-333090.md) | [13.4](/filings/0001193125-25-267093.md) | [(77.6) d](/filings/0001193125-26-055059.md) | [5.7](/filings/0001193125-26-206810.md) | [2.4](/filings/0001193125-26-333090.md) |
| Income tax | $m | [(1.5)](/filings/0000950170-24-123004.md) | [(5.7) d](/filings/0001193125-26-055059.md) | [1.8](/filings/0000950170-25-062012.md) | [9.1](/filings/0000950170-25-104199.md) | [11.5](/filings/0001193125-25-267093.md) | [8.1 d](/filings/0001193125-26-055059.md) | [15.6](/filings/0001193125-26-206810.md) | [22.1](/filings/0001193125-26-333090.md) | [54.9](/filings/0001193125-25-267093.md) | [53.9 d](/filings/0001193125-26-055059.md) | [50.9](/filings/0001193125-26-206810.md) | [18.8](/filings/0001193125-26-333090.md) |
| Net income | $m | [(22.4)](/filings/0000950170-24-123004.md) | [(42.9) d](/filings/0001193125-26-055059.md) | [(5.8)](/filings/0000950170-25-062012.md) | [27.9](/filings/0000950170-25-104199.md) | [1.8](/filings/0001193125-25-267093.md) | [11.9 d](/filings/0001193125-26-055059.md) | [28.9](/filings/0001193125-26-206810.md) | [57.7](/filings/0001193125-26-333090.md) | [101](/filings/0001193125-25-267093.md) | [134 d](/filings/0001193125-26-055059.md) | [(19.0)](/filings/0001193125-26-206810.md) | [118](/filings/0001193125-26-333090.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-123004.md) | not reported | [(0.01)](/filings/0000950170-25-062012.md) | [0.04](/filings/0000950170-25-104199.md) | [0.00](/filings/0001193125-25-267093.md) | not reported | [0.05](/filings/0001193125-26-206810.md) | [0.09](/filings/0001193125-26-333090.md) | [0.15](/filings/0001193125-25-267093.md) | not reported | [(0.03)](/filings/0001193125-26-206810.md) | [0.17](/filings/0001193125-26-333090.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-123004.md) | not reported | [(0.01)](/filings/0000950170-25-062012.md) | [0.04](/filings/0000950170-25-104199.md) | [0.00](/filings/0001193125-25-267093.md) | not reported | [0.05](/filings/0001193125-26-206810.md) | [0.09](/filings/0001193125-26-333090.md) | [0.15](/filings/0001193125-25-267093.md) | not reported | [(0.03)](/filings/0001193125-26-206810.md) | [0.18](/filings/0001193125-26-333090.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [101](/filings/0000950170-23-059922.md) | [106](/filings/0001193125-26-055059.md) | [80.2](/filings/0000950170-25-062012.md) | [24.6](/filings/0000950170-25-104199.md) | [22.3](/filings/0001193125-25-267093.md) | [26.9](/filings/0001193125-26-055059.md) | [23.7](/filings/0001193125-26-206810.md) | [297](/filings/0001193125-26-333090.md) | [134](/filings/0001193125-25-267093.md) | [242](/filings/0001193125-26-333090.md) | [588](/filings/0001193125-26-206810.md) | [483](/filings/0001193125-26-333090.md) |
| Current assets | $m | [248](/filings/0000950170-23-059922.md) | [260](/filings/0000950170-25-019955.md) | [255](/filings/0000950170-24-056495.md) | [200](/filings/0000950170-24-092450.md) | [206](/filings/0000950170-24-123004.md) | [214](/filings/0001193125-26-055059.md) | [246](/filings/0000950170-25-062012.md) | [515](/filings/0000950170-25-104199.md) | [388](/filings/0001193125-25-267093.md) | [629](/filings/0001193125-26-333090.md) | [958](/filings/0001193125-26-206810.md) | [772](/filings/0001193125-26-333090.md) |
| Total assets | $m | [2,961](/filings/0000950170-23-059922.md) | [3,011](/filings/0001193125-26-055059.md) | [2,994](/filings/0000950170-24-056495.md) | [2,940](/filings/0000950170-24-092450.md) | [2,956](/filings/0000950170-24-123004.md) | [2,981](/filings/0001193125-26-055059.md) | [3,024](/filings/0000950170-25-062012.md) | [3,309](/filings/0000950170-25-104199.md) | [3,222](/filings/0001193125-25-267093.md) | [3,561](/filings/0001193125-26-333090.md) | [3,376](/filings/0001193125-26-206810.md) | [3,185](/filings/0001193125-26-333090.md) |
| Current liabilities | $m | [145](/filings/0000950170-23-059922.md) | [157](/filings/0000950170-25-019955.md) | [153](/filings/0000950170-24-056495.md) | [156](/filings/0000950170-24-092450.md) | [189](/filings/0000950170-24-123004.md) | [198](/filings/0001193125-26-055059.md) | [173](/filings/0000950170-25-062012.md) | [193](/filings/0000950170-25-104199.md) | [180](/filings/0001193125-25-267093.md) | [232](/filings/0001193125-26-333090.md) | [194](/filings/0001193125-26-206810.md) | [149](/filings/0001193125-26-333090.md) |
| Total liabilities | $m | [983](/filings/0000950170-23-059922.md) | [1,043](/filings/0000950170-25-019955.md) | [1,036](/filings/0000950170-24-056495.md) | [960](/filings/0000950170-24-092450.md) | [917](/filings/0000950170-24-123004.md) | [942](/filings/0001193125-26-055059.md) | [950](/filings/0000950170-25-062012.md) | [999](/filings/0000950170-25-104199.md) | [772](/filings/0001193125-25-267093.md) | [969](/filings/0001193125-26-333090.md) | [805](/filings/0001193125-26-206810.md) | [507](/filings/0001193125-26-333090.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-019955.md) | not reported | not reported | [35.9](/filings/0000950170-24-123004.md) | [33.6](/filings/0001193125-26-055059.md) | [33.6](/filings/0000950170-25-062012.md) | [35.4](/filings/0000950170-25-104199.md) | [0.0](/filings/0001193125-25-267093.md) | [0.0](/filings/0001193125-26-055059.md) | not reported | not reported |
| Shareholders' equity | $m | [1,978](/filings/0000950170-24-123004.md) | [1,968](/filings/0001193125-26-055059.md) | [1,959](/filings/0000950170-25-104199.md) | [1,980](/filings/0001193125-25-267093.md) | [2,038](/filings/0001193125-25-267093.md) | [2,040](/filings/0001193125-26-333090.md) | [2,074](/filings/0001193125-26-333090.md) | [2,310](/filings/0001193125-26-333090.md) | [2,450](/filings/0001193125-25-267093.md) | [2,592](/filings/0001193125-26-333090.md) | [2,571](/filings/0001193125-26-333090.md) | [2,678](/filings/0001193125-26-333090.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.2 d](/filings/0000950170-24-123004.md) | [0.9 d](/filings/0001193125-26-055059.md) | [17.1](/filings/0000950170-25-062012.md) | [78.7 d](/filings/0000950170-25-104199.md) | [55.0 d](/filings/0001193125-25-267093.md) | [67.5 d](/filings/0001193125-26-055059.md) | [35.7](/filings/0001193125-26-206810.md) | [162 d](/filings/0001193125-26-333090.md) | [148 d](/filings/0001193125-25-267093.md) | [217 d](/filings/0001193125-26-055059.md) | [194](/filings/0001193125-26-206810.md) | [175 d](/filings/0001193125-26-333090.md) |
| Capital expenditure | $m | [55.4 d](/filings/0000950170-24-123004.md) | [62.6 d](/filings/0001193125-26-055059.md) | [47.6](/filings/0000950170-25-062012.md) | [50.4 d](/filings/0000950170-25-104199.md) | [55.7 d](/filings/0001193125-25-267093.md) | [60.8 d](/filings/0001193125-26-055059.md) | [37.8](/filings/0001193125-26-206810.md) | [42.7 d](/filings/0001193125-26-333090.md) | [89.5 d](/filings/0001193125-25-267093.md) | [82.3 d](/filings/0001193125-26-055059.md) | [39.3](/filings/0001193125-26-206810.md) | [39.1 d](/filings/0001193125-26-333090.md) |
| Dividends paid | $m | [3.9 d](/filings/0000950170-24-123004.md) | [4.0 d](/filings/0001193125-26-055059.md) | [4.0](/filings/0000950170-25-062012.md) | [4.0 d](/filings/0000950170-25-104199.md) | [8.7 d](/filings/0001193125-25-267093.md) | [8.6 d](/filings/0001193125-26-055059.md) | [2.5](/filings/0001193125-26-206810.md) | [2.5 d](/filings/0001193125-26-333090.md) | [2.7 d](/filings/0001193125-25-267093.md) | [2.7 d](/filings/0001193125-26-055059.md) | [2.8](/filings/0001193125-26-206810.md) | [2.5 d](/filings/0001193125-26-333090.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123004.md) | [0.0 d](/filings/0001193125-26-055059.md) | [1.2](/filings/0000950170-25-062012.md) | [0.0 d](/filings/0000950170-25-104199.md) | [0.0 d](/filings/0001193125-25-267093.md) | [0.0 d](/filings/0001193125-26-055059.md) | [0.0](/filings/0001193125-26-206810.md) | [0.9 d](/filings/0001193125-26-333090.md) | [0.0 d](/filings/0001193125-25-267093.md) | [0.0 d](/filings/0001193125-26-055059.md) | [1.2](/filings/0001193125-26-206810.md) | [3.4 d](/filings/0001193125-26-333090.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [555](/filings/0000950170-23-059922.md) | [600](/filings/0000950170-24-056495.md) | [604](/filings/0000950170-24-092450.md) | [608](/filings/0000950170-24-123004.md) | [616](/filings/0000950170-25-062012.md) | [622](/filings/0000950170-25-104199.md) | [626](/filings/0001193125-25-267093.md) | [635](/filings/0001193125-26-206810.md) | [640](/filings/0001193125-26-333090.md) | [672](/filings/0001193125-25-267093.md) | [675](/filings/0001193125-26-206810.md) | [676](/filings/0001193125-26-333090.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 671,768,431 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-333090.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.